One World Cannabis to Offer New Alternative Treatment for Chronic Pain

The announcement comes after the FDA warning on new dangers from pain killers like Ibuprofen.


One World Cannabis

One World Cannabis Ltd, a wholly owned subsidiary of Israel’s OWC Pharmaceutical Research Corp. (OTCQB: OWCP) which develops cannabinoid-based therapies targeting a variety of different indications, is offering new and alternative hope to patients diagnosed with chronic pain.

The company has already filed two provisional patent applications with the USPTO related to the development of two unique formulations that include cannabis extracts and a new delivery system to treat fibromyalgia and migraines, and has begun researching and developing new cannabis-based therapies to help alleviate the suffering of patients experiencing enduring pain.

The news comes after the FDA recently announced that there is a greater risk of heart attacks and strokes from both over-the-counter and prescription non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), which are typically used to treat chronic pain.

The company asserts that the cannabis-based novel treatment employed by One World Cannabis could be an alternative to NSAIDs to treat long-lasting pain and fever from many different long- and short-term medical conditions. In addition, the cannabis-based treatment will provide physicians, as well as patients, with the ability to control and administrate optimal dosage, thus offering an alternative to current delivery systems that are not acceptable to scientists and physicians, such as smoking marijuana, edibles and oil extracts with no substantial dosage control.

“Chronic pain represents an emerging public health issue of massive proportions, ” said Dr. Yehuda Baruch, Director of Research and Regulatory Affairs. “In light of the latest FDA calling on NSAIDs makers, One World Cannabis believes that our cannabis-based products and treatments will be an effective and safe alternative to acute and chronic treatment of pain.”

One World Cannabis also plans to start researching the relief of migraine attack symptoms, again by using a formulation comprising, inter alia, a therapeutically effective amount of Tetrahydrocannabinol (THC), Cannabidiol (CBD). The clinical trial, as its protocol is written nowadays, will be conducted by the company in collaboration with another Israeli leading academic medical center.

Read more about: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Email:

Delivered by FeedBurner